TICKERNERD
Menu
RPIDRPIDHealthcare · Medical Devices

RPID Stock Forecast: Rapid Micro Biosystems, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.23
+2.50% on the day

The 4 Wall Street analysts covering Rapid Micro Biosystems, Inc. hold a median 12-month price target of $7 — +469.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$60.2M
Ticker Nerd rank
28 / 100
Median analyst target
$7.00
Analysts covering
4
Revenue$8.1M+10.9% y/y
Operating income−$12.3M
Net income−$12.9M
Free cash flow−$12.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.9%
1M
−27.2%
YTD
−57.6%
1Y
−58.0%
From 52W high
−73.7%
From 52W low
+2.5%
$1.20
$4.68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RPID stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rapid Micro Biosystems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
86
Size
80
Revisions
50
Volatility
50
Quality
34
Value
30
Growth
30
Momentum
11
Issuance
10

Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RPID stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RPID, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26RPIDHigh $8.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $5.00Median $7.00High $8.00

The green dot is the last close — the median target sits +469.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 May 2026KeybancMaintainsOverweight$8.00 → $5.00
22 May 2026Lake StreetMaintainsBuy$8.00 → $7.00
28 July 2025Lake StreetInitiatesBuy—
12 Feb 2025KeybancInitiatesOverweight—
7 Mar 2023Morgan StanleyReiteratesEqual-Weight—
16 Aug 2022JP MorganDowngradeNeutral—
11 May 2022Morgan StanleyMaintainsEqual-Weight—
7 Mar 2022Morgan StanleyMaintainsEqual-Weight—
15 Feb 2022Morgan StanleyMaintainsEqual-Weight—
15 Nov 2021Morgan StanleyMaintainsEqual-Weight—
9 Aug 2021Cowen & Co.InitiatesOutperform—
9 Aug 2021JP MorganInitiatesOverweight—
9 Aug 2021Morgan StanleyInitiatesEqual-Weight—
9 Aug 2021StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RPID appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RPID vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Rapid Micro Biosystems, Inc. returned −58.0% against +17.5% for the S&P 500, dividends included.

RPID vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Oct 25Jan 26Apr 26Jul 26RPIDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RPID analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Rapid Micro Biosystems, Inc. (RPID) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.1×

Cheaper than 83% of US stocks

Price / sales
1.7×

Cheaper than 57% of US stocks

Price / book
3.4×

Cheaper than 29% of US stocks

EV / EBITDA
−1.3×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
10.9%

Higher than 55% of US stocks

Earnings growth (YoY)
10.9%

Higher than 49% of US stocks

Gross margin
15.0%

Higher than 14% of US stocks

Operating margin
−153.0%

Higher than 12% of US stocks

Net margin
−145.6%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−141.6%

Higher than 10% of US stocks

Return on assets
−46.4%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rapid Micro Biosystems, Inc. (RPID) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rapid Micro Biosystems, Inc. has a market value of $60.2M and an enterprise value of $63.2M.

  • Revenue in the twelve months to 30 June 2026: $35.2M. The latest quarter grew 10.9% year on year.

  • Net income over the same four quarters: −$51.2M, a −145.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.12.

  • Free cash flow in the twelve months to 30 June 2026: −$40.4M.

  • Shares outstanding: 50.0M.

  • Trailing P/E: −1.1×; forward P/E: −1.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Rapid Micro Biosystems, Inc. employs 171 people — $206K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

RPID vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
RPIDRapid Micro Biosystems, Inc.$60.2M
28
OMOutset Medical, Inc.$58.7M
29
COCHEnvoy Medical, Inc.$56.9M
34
NNOXNano-X Imaging Ltd.$56.9M
19
SRTSSensus Healthcare, Inc.$51.8M
51
MYOMyomo, Inc.$51.5M
52
CVRXCVRx, Inc.$75.8M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rapid Micro Biosystems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RPID news & analysis

Rapid Micro Biosystems to Participate in Upcoming Investor Conferences

GlobeNewsWire · 4 Sept 2026neutral

Rapid Micro Biosystems, Inc. announced that it plans to participate in several upcoming investor conferences. The company, which provides automation solutions for healthcare product manufacturing, shared this through a press release from its Lexington, Massachusetts headquarters.

Why it matters — RPID watchers would be interested since investor conference participation offers management the opportunity to present the company's strategy and operations to the investment community, making it a routine but notable corporate activity.

After Plunging 33.7% in 4 Weeks, Here's Why the Trend Might Reverse for Rapid Micro Biosystems (RPID)

Zacks Investment Research · 4 Sept 2026positive

Rapid Micro Biosystems (RPID) is described as technically oversold after falling 33.7% over four weeks. The article notes that analysts have been revising earnings estimates upward, which together suggests a possible near-term trend reversal for the stock.

Why it matters — A RPID watcher would care because the combination of oversold technical conditions and upward earnings estimate revisions could signal that the stock's recent decline may be coming to an end.

Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)

Zacks Investment Research · 19 Aug 2026positive

Rapid Micro Biosystems (RPID) shares have fallen 25.7% over the past four weeks and are now technically in oversold territory. Wall Street analysts show strong agreement in revising earnings estimates upward, which the piece suggests could signal a trend reversal.

Why it matters — RPID watchers would care because the combination of an oversold technical reading and upward analyst estimate revisions could indicate a shift in the stock's recent downward trajectory.

Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 12 Aug 2026positive

Rapid Micro Biosystems (RPID) was upgraded to a Zacks Rank #2 (Buy). The upgrade reflects growing optimism about the company's earnings prospects.

Why it matters — The upgrade signals a change in analyst sentiment toward RPID's earnings outlook that watchers of the stock may find notable.

Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Rapid Micro Biosystems, Inc. (RPID) held its Q2 2026 earnings call, and the transcript of that call was published by Seeking Alpha. The call covered the company's second-quarter 2026 financial results and related discussion.

Why it matters — RPID watchers can review the full Q2 2026 earnings call transcript to hear management's commentary on the company's recent performance and outlook.

FAQ

Frequently asked questions about RPID stock

What is the RPID stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Rapid Micro Biosystems, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RPID stock a buy right now?

Of the 4 analysts covering Rapid Micro Biosystems, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapid Micro Biosystems, Inc. 28 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RPID?

As at 12 Sept 2026, Rapid Micro Biosystems, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).

Will RPID stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +469.1% from the last close, and Ticker Nerd's factor model ranks Rapid Micro Biosystems, Inc. 28 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RPID stock forecast for 2030?

No analyst covering Rapid Micro Biosystems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RPID are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.

How has RPID stock performed over the past year?

Rapid Micro Biosystems, Inc. returned -58.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rapid Micro Biosystems, Inc. do?

Rapid Micro Biosystems Inc. Class A Common Stock represents ownership in Rapid Micro Biosystems, a life sciences technology company focused on automated microbial quality control for the pharmaceutical and biopharmaceutical industries.

What is the latest news on RPID?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Rapid Micro Biosystems to Participate in Upcoming Investor Conferences". Rapid Micro Biosystems, Inc. announced that it plans to participate in several upcoming investor conferences. The company, which provides automation solutions for healthcare product manufacturing, shared this through a press release from its Lexington, Massachusetts headquarters.

Company

About Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems Inc. Class A Common Stock represents ownership in Rapid Micro Biosystems, a life sciences technology company focused on automated microbial quality control for the pharmaceutical and biopharmaceutical industries. The company develops mission-critical solutions that help manufacturers detect microbial contamination and support the efficient manufacturing and safe release of healthcare products. Its current offerings include the Growth Direct platform, which combines an automated system, proprietary consumables, software for laboratory information management system connectivity, and validation and support services. These products are used across regulated environments involved in biologics, vaccines, cell and gene therapies, sterile injectables, medical devices, and personal care products. Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems serves customers in the United States and international markets, where faster and more reliable microbial testing plays an important role in modern production workflows.

CEO Mr. Robert G. Spignesi Jr. · 171 employees · United States · https://www.rapidmicrobio.com